Larvol Delta - FAVOUR-Study-of-FURMONERTINIB-in-Patients-With-NSCLC-Having-Exon-20-Insertion-Mutation

Ivesa (firmonertinib) - Allist, ArriVent

http://clinicaltrials.gov/ct2/show/NCT04858958

Aug 14, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next